Gavin Stuart

12.1k total citations · 2 hit papers
118 papers, 6.1k citations indexed

About

Gavin Stuart is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Epidemiology. According to data from OpenAlex, Gavin Stuart has authored 118 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Reproductive Medicine, 49 papers in Obstetrics and Gynecology and 45 papers in Epidemiology. Recurrent topics in Gavin Stuart's work include Ovarian cancer diagnosis and treatment (54 papers), Endometrial and Cervical Cancer Treatments (47 papers) and Cervical Cancer and HPV Research (44 papers). Gavin Stuart is often cited by papers focused on Ovarian cancer diagnosis and treatment (54 papers), Endometrial and Cervical Cancer Treatments (47 papers) and Cervical Cancer and HPV Research (44 papers). Gavin Stuart collaborates with scholars based in Canada, United States and United Kingdom. Gavin Stuart's co-authors include Ignace Vergote, Jill Nation, Ángel J. Lacave, Tom Ehlen, Gunnar B. Kristensen, Corneel Coens, Antonio Casado, Nick Johnson, N.S. Reed and René H.M. Verheijen and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Gavin Stuart

116 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

2010 1.7k citations Ignace Vergote, Gunnar B. Kristensen et al. profile →
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

2006 540 citations Ignace Vergote, Gavin Stuart et al. profile →

Peers

Countries citing papers authored by Gavin Stuart

Since Specialization

Citations

This map shows the geographic impact of Gavin Stuart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Stuart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Stuart more than expected).

Fields of papers citing papers by Gavin Stuart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin Stuart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Stuart. The network helps show where Gavin Stuart may publish in the future.

Co-authorship network of co-authors of Gavin Stuart

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Stuart. A scholar is included among the top collaborators of Gavin Stuart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin Stuart. Gavin Stuart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study 2024 ·Cancer Epidemiology Biomarkers & Prevention ·Anna Gottschlich, Quan Hong, Lovedeep Gondara, (unknown), Darrel Cook, Ruth Elwood Martin, Marette Lee, Joy Melnikow, Stuart Peacock, Lily Proctor, Gavin Stuart, Eduardo L. Franco, Mel Krajden, Laurie Smith, Gina Ogilvie	1
2	Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study 2023 ·The Lancet Regional Health - Americas ·Anna Gottschlich, Lovedeep Gondara, Laurie Smith, (unknown), Darrel Cook, Mel Krajden, Marette Lee, Ruth Elwood Martin, Joy Melnikow, Stuart Peacock, Lily Proctor, Gavin Stuart, Eduardo L. Franco, Dirk van Niekerk, Gina Ogilvie	3
3	Cost‐effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial 2021 ·Cancer Medicine ·(unknown), Laurie Smith, (unknown), Lindsay Hedden, Andrew J. Coldman, Darrel Cook, Eduardo L. Franco, Mel Krajden, Ruth Elwood Martin, Marette Lee, Gavin Stuart, Dirk van Niekerk, Gina Ogilvie, Stuart Peacock	14
4	Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort 2020 ·Cancer Epidemiology Biomarkers & Prevention ·Anna Gottschlich, Dirk van Niekerk, Laurie Smith, Lovedeep Gondara, Joy Melnikow, Darrel Cook, Marette Lee, Gavin Stuart, Ruth Elwood Martin, Stuart Peacock, Eduardo L. Franco, Andrew J. Coldman, Mel Krajden, Gina Ogilvie	16
5	Disease detection at the 48‐month exit round of the HPV FOCAL cervical cancer screening trial in women per‐protocol eligible for routine screening 2019 ·International Journal of Cancer ·Andrew J. Coldman, Dirk van Niekerk, Mel Krajden, Laurie Smith, Darrel Cook, Lovedeep Gondara, Kathy Ceballos, (unknown), Marette Lee, (unknown), Laura Gentile, Stuart Peacock, Gavin Stuart, Eduardo L. Franco, Gina Ogilvie	2
6	Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials 2019 ·Obstetrical & Gynecological Survey ·Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B. Kristensen, Mahesh Parmar, Tom Ehlen, Gordon C. Jayson, Nick Johnson, (unknown), René H.M. Verheijen, W. Glenn McCluggage, Timothy Perren, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Gavin Stuart, N.S. Reed, Sean Kehoe	30
7	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial 2018 ·Obstetrical & Gynecological Survey ·Gina Ogilvie, Dirk van Niekerk, Mel Krajden, Laurie Smith, Darrel Cook, Lovedeep Gondara, Kathy Ceballos, David Quinlan, Marette Lee, Ruth Elwood Martin, Laura Gentile, Stuart Peacock, Gavin Stuart, Eduardo L. Franco, Andrew J. Coldman	32
8	Future opportunities of the Gynecological Cancer Intergroup 2008 ·International Journal of Gynecological Cancer ·Gavin Stuart	1
9	Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control 2004 ·Journal of Obstetrics and Gynaecology Canada ·Gavin Stuart, Gregory Taylor, Christina Bancej, (unknown), Terence J. Colgan, Eduardo L. Franco, Rhonda Y. Kropp, Robert Lotocki, Verna Mai, C. Meg McLachlin, Jay Onysko, Ruth Elwood Martin	16
10	First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel-epirubicin-carboplatin (TEC) vs paclitaxel-carboplatin (TC). Interim results of an NSGO-EORTC GCG - NCIC CTG intergroup Phase III study 2002 ·International Journal of Gynecological Cancer ·Ignace Vergote, Gunnar B. Kristensen, Gavin Stuart, (unknown), J. Kærn, E. A. Eisenhauer	4
11	Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer 2002 ·Annals of Oncology ·Martine Piccart, K. Bertelsen, Gavin Stuart, J Cassidy, Ignace Vergote, (unknown), K. Swenerton, (unknown), Jean Roy, B. Barón	5
12	Evidence of a role for the INK4 family of cyclin‐dependent kinase inhibitors in ovarian granulosa cell tumors 2002 ·Genes Chromosomes and Cancer ·Mayi Arcellana‐Panlilio, R. Maarten Egeler, (unknown), Anthony Magliocco, Gavin Stuart, Stephen M. Robbins, Max J. Coppes	19
13	Management of Aggressive Histologic Variants of Endometrial Carcinoma at the Tom Baker Cancer Centre between 1984 and 1994 2000 ·Gynecologic Oncology ·Peter Craighead, Khalid Sait, Gavin Stuart, Keith Arthur, Jill Nation, Máire A. Duggan, Dianlin Guo	57
14	Urolithiasis Following Formation of a Continent Urostomy: Case Report and Review of the Literature 2000 ·Gynecologic Oncology ·Khalid Sait, Gavin Stuart, Jill Nation, Prafull Ghatage	2
15	1999 ·Annals of Oncology ·(unknown), Gavin Stuart, (unknown), (unknown), Mahesh Parmar, E. A. Eisenhauer, (unknown), (unknown), (unknown), (unknown), Jan B. Vermorken	2
16	Review of the screening history of Alberta women with invasive cervical cancer. 1997 ·PubMed ·Gavin Stuart, S. Elizabeth McGregor, Máire A. Duggan, Jill Nation	49
17	Cervical cancer screening: are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix. 1996 ·PubMed ·(unknown), G. Harvey Anderson, Emily A Clarke, (unknown), (unknown), (unknown), (unknown), (unknown), Gavin Stuart, Sylvie Stachenko	20
18	Uterine Atypical Polypoid Adenomyoma and Ovarian Endometrioid Carcinoma 1995 ·International Journal of Gynecological Pathology ·Máire A. Duggan, (unknown), (unknown), Jill Nation, Gavin Stuart	8
19	Phase II Study to Evaluate the Toxicity and Efficacy of Concurrent Cisplatin and Radiation Therapy in the Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Cervix 1995 ·Gynecologic Oncology ·R. Pearcey, Gavin Stuart, Grant D. MacLean, Jill Nation, Keith Arthur, Himu Lukka, John Jeffrey, Keith James, Michael Brundage	29
20	Evaluation of surgical staging in stage I low malignant potential ovarian tumors 1991 ·Gynecologic Oncology ·(unknown), Gavin Stuart, Jill Nation, D. Ian Robertson	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact